Abstract We examined the effect of
Introduction
PF1022A, a newly developed anthelmintic in Japan (Takagi et al. 1991 ) with a cyclic depsipeptide structure, has been identified to be effective in vivo as well as in vitro against intestinal nematodes (Sasaki et al. 1992 ). In the in vitro study of Angiostrongylus cantonensis, Terada (1992) found that PF1022A paralyzed worms by stimulating the gabergic mechanism and inhibiting the cholinergic mechanism synergistically. It is well known that the motility of nematodes is regulated by an excitatory cholinergic mechanism and an inhibitory gabergic mechanism (Natoff 1969; Martin et al. 1991) . Some of the anthelmintics with antinematodal activity have been characterized to inhibit the cholinergic mechanism in isolated frog rectus preparations (Terada et al. 1994 ) at concentrations higher than that stimulating the gabergic mechanism, which is responsible for paralysis of the nematode (Martin et al. 1991) . Gabergic inhibition seems to be the major antinematodal action of PF1022A, although the real mechanisms have remained obscure to date. To understand the direct effect of PF1022A on gabergic receptors, the present study was carried out using a radioligand binding assay in Ascaris suum, another nematode that is suitable because it contains more membrane protein, and the presence of gabergic transmission was estimated ).
Materials and methods

Preparation of membrane protein
Ascaris suum specimens were collected at a slaughterhouse and transported to the laboratory in a Tyrode-Ringer solution. The worms were kept in glass holders containing Tyrode-Ringer solution under continuous aeration with room air at 37±1°C. The solution was changed at least three times daily. After maintenance in the laboratory for more than 2 days, adult worms of 25-to 30-cm length were used. Somatic muscle of the worms was prepared as previously described (Norton and De Beer 1957) . The cephalad half-inch containing the main ganglia was cut off. The worm was then split along one side and the intestine was gently removed to reveal the muscle bag cells. An anterior section of the worm, approximately 8 cm long, was excised for homogenation in 20 vol. (w/v) of ice-cold 50 mM TRIS buffer (pH 7.4). The homogenate was centrifuged at 5,000 g for 10 min and the supernatant was collected. After centrifugation of the homogenate at 80,000 g for 30 min, the pellet was rehomogenized and recentrifuged twice as described above. The final pellet was then rehomogenized in 50 mM TRIS buffer (pH 7.4) containing 120 mM NaCl, 5 mM KCl, 2 mM
Characterization of subtypes of gamma-aminobutyric acid receptors in an Ascaris muscle preparation by binding assay and binding of PF1022A, a new anthelmintic, on the receptors CaCl 2 , and 1 mM MgCl 2 for preparation of the crude membrane suspension. Then, aliquots were taken with the desired amount of protein. The protein content was determined as described previously (Lowry et al. 1951 ).
Radioligand binding study
Aliquots of the obtained suspension were incubated in the presence of various concentrations of radioligand. Nonspecific binding was obtained in separate assays containing an unlabeled antagonist at 1 µM. In the present study, in addition to the basic study of GABA binding using unlabeled GABA as an antagonist, we used [methyl-3 H]-bicuculline as the radioligand for GABA A receptors, and [butyl-4-3 H]-baclofen was employed to identify the GABA B receptors. Incubation was performed at 25±1°C in a shaking water bath for 60 min. Bound and free radioligand were then separated by filtration under vacuum through Whatman GF/B glass fiber filters, followed immediately by two washes with 10 ml ice-cold 50 mM TRIS buffer (pH 7.4). The radioactivity on the filters was measured in a liquid scintillation counter (Beckman LS 5000TA).
The obtained values, run in triplicate, were used for Scatchard analysis using the EBDA program on a computer (Cheng et al. 1990) . A competition experiment was also carried out; the unlabeled compound at various concentrations was allowed to compete with a fixed concentration of radioligand. According to a previous report (Cheng and Prusoff 1973) , we compared the activity of test inhibition constants compounds in terms of (K i values). The K i values were calculated using the relationship
, where IC 50 is the concentration of a compound needed to displace 50% of the specific binding of radioligand, L is the fixed concentration of radioligand, and K d is the dissociation constant of the radioligand.
Drugs
The following drugs, obtained from commercial sources, were used: 5-aminovaleric acid, isoguvacine, gabazine (SR-95531), phaclofen, and thiomuscimol, from Research Biochemicals International (RBI, Natick, Mass., USA); and 4-amino-n-butyric acid (GABA), baclofen, (-)-bicuculline methiodide, muscimol, picrotoxin, and piperazine, from Sigma Chemicals (St. Louis, Mo., USA). PF1022A was kindly supplied by Meiji Seika Kaisha (Tokyo, Japan). All the drug solutions were prepared as stock solutions with double-distilled water, and fresh dilutions were made up daily in TRIS-buffer solution. All water-insoluble compounds were dissolved in dimethylsulfoxide (DMSO) except for PF1022A, which was prepared in methanol. The vehicle solution was made in the same manner but without the addition of test substances. The radioligands [2, 
Results
In the obtained pellet, an increase in binding with time was observed after incubation of 0.1 nM [2,3-3 H(N)]-GABA until equilibrium had been reached at 45 min. The binding of [2, H(N)]-GABA was linear with increasing concentrations of membrane pellet up to 1.8 mg protein (n=6). Then, various concentrations of radioactive GABA were incubated. When binding was evaluated as a function of radioligand concentration, saturation of specific sites was clearly achieved, whereas nonspecific binding increased linearly over the entire concentration range tested. Figure 1 shows the saturation kinetics observed for the specific binding of [2, 
H(N)]-GABA in
Ascaris muscle-cell membrane after incubation with increasing concentrations of radioligand. Linear leastsquares fitting to the specific binding data gave a K d value of 540 nM, whereas the maximal number of binding sites (B max ) amounted to 4.92±0.29 pmol/mg protein (mean ±SD, n=6). The slope of the Hill plot (0.98±0.07) was not significantly different from unity. The rate of dissociation from [2, H(N)-GABA binding sites was calculated after the incubation of membrane pellets for 60 min followed by the addition of 1 µM GABA for measurement of the specific binding at 5-min intervals thereafter. The half-time for dissociation was calculated as 14 min. Also, incubation with [methyl-3 H]-bicuculline in the presence of 1 µM bicuculline showed a linear specific binding (Hill plot, 087±0.24) , with the K d value being 1.96 nM and B max value being 0.84±0.08 pmol/mg protein (n=6).
The ability of PF1022A to displace the binding of [2, a K i values (mean ±SD) were calculated from 6 experiments according to the formula of Cheng and Prusoff (1973) . Lower values mean a greater activity to displace the binding of radioligand& / t b l . b : pounds tested. Unlabeled GABA was the most potent compound tested, whereas muscimol possessed activity similar to that of PF1022A. As judged among the agents selective for GABA A receptors, the K i value of PF1022A, i.e., the ability to displace the binding of radioligand, seemed similar to those of isoguvacine and gabazine. Moreover, the capacity of piperazine to displace the binding of [2,3-3 H(N)]-GABA and [methyl-3 H]-bicuculline was lower than that of PF1022A. However, the piperazine concentrations needed to displace [methyl-3 H]-bicuculline binding were 10-fold higher than those required to displace [2,3-3 H(N)-GABA binding, and the same factor of difference was also observed for PF1022A (Table 1) .
In further experiments seeking GABA B receptor binding, we used [butyl-4-3 H]-baclofen as the radioligand and phaclofen (1 µM) as the antagonist. Figure 2 shows the saturation kinetics observed for the specific binding of [butyl-4-3 H]-baclofen in the membrane preparation after incubation with increasing amounts of radioligand. Scatchard plotting of the specific binding data gave a K d value of 0.01 nM (n=6), whereas the B max value was only 35.9±3.7 fmol/mg protein. However, the slope of the Hill plot (0.94±0.16) was not markedly different from unity (Fig. 2) .
PF1022A decreased the binding of [butyl-4-3 H]-baclofen, a ligand for GABA B receptors, in a concentration-dependent manner. In Table 2 , the K i value of PF1022A is compared with that of other compounds.
Only those compounds with a chemical structure similar to baclofen could inhibit [butyl-4-3 H]-baclofen binding. As compared with baclofen-like compounds, the ability of PF1022A to displace the binding of [butyl-4-3 H]-baclofen was lower, i.e., the K i value was more than 100-fold higher. Piperazine, thiomuscimol, and GABA did not displace the binding of [butyl-4-3 H]-baclofen. Clearly, the PF1022A concentrations effective for binding to GABA B receptors are higher than those required to affect [methyl-3 H]-bicuculline binding, which is specific for GABA A receptors. Furthermore, the slope generated for PF1022A-induced displacement of [butyl-4-3 H]-baclofen binding was different from unity (Table 2) .
Discussion
The present study shows that PF1022A can displace radioligands specific for GABA receptor binding in isolated Ascaris suum somatic muscles. By recording of membrane potentials in isolated Ascaris somatic muscles, the presence of GABA A receptors has been established ). The results we obtained using the radioligand binding study support this view (Fig. 1) . The linear slope of [2,3-3 H(N)]-GABA specific binding indicated the presence of a single binding site. The data obtained for K d and B max were close to those mentioned for high-affinity GABA receptors in mammalian brain (Falch and Krogsgaard-Larsen 1982) .
In mammalian tissues, two subtypes of receptors for GABA, GABA A and GABA B , are present (Alger and Nicoll 1982) , depending on the sensitivity or lack of sensitivity to bicuculline (Hill and Bowery 1981) . Activation of the GABA A receptor opens a chloride ion channel (Stephenson 1988) , which can also be regulated by benzodiazepine (Pritchett et al. 1989 ). The GABA B subtype is known as an autoreceptor that is coupled to pertussis toxin-sensitive quanosine triphosphate (GTP)-binding protein (Davies et al. 1991) . In general, the GABA A receptor is believed to exist as ligand-gated chloride ion channels modulated by multiple drug-binding sites (Sieghart 1992) , whereas muscimol and bicuculline are the popularly used radioligands (Bureau and Olsen 1990) .
In invertebrates, GABA receptors do not readily fit into the subtypes mentioned in mammalian tissues . In Ascaris muscle, as described in skeletal muscle in mammalians (Baldwin and Moyle 1949) , the response to GABA is accompanied by an increase in the conductance of the membrane for chloride ions (Martin 1980) . As judged from data obtained in electrophysiology studies, only the GABA A receptor is present in Ascaris muscle . The result we obtained for linear binding of radioactive GABA is totally in agreement with this view, although it is unlike the two-affinity binding sites described in mammalinan brain (Falch and KrogsgaardLarsen 1982) . Parallel to the concentration-dependent inhibition of radioactive GABA binding, PF1022A displaced the binding of [methyl-3 H]-bicuculline at a higher concentration and showed a level of activity (K i ) close to that induced by agents selective for GABA A receptors (Table 1) . A direct effect of PF1022A on GABA A receptors can thus be considered. This supports our previous suggestion that PF1022A functions as a gabergic anthelmintic compound (Terada 1992) . Also, we found that piperazine could displace the binding of [2, H(N)]-GABA and [methyl-3 H]-bicuculline in a way similar to that of PF1022A. This result is consistent with a previous suggestion regarding the gabergic action of piperazine in A. suum muscle (Onuaguluchi 1989) . Bicuculline is one of the specific antagonists for GABA A receptors (Walker et al. 1971) , although Ascaris muscle is less sensitive to it (Smart and Constanti 1986) . The linear slope of [methyl-3 H]-bicuculline specific binding in the presence of unlabeled bicuculline indicates a single binding site at K d and B max values similar to those found in mammalian brain (Möhler and Okada 1978) .
Recently, a subtype of the GABA A receptors has been proposed (Burt and Kamatchi 1991) , and this is helpful in explaing why the concentrations of PF1022A and piperazine needed to displace [methyl-3 H]-bicuculline binding are higher than those required to compete with the binding of [2, H(N)]-GABA. Multiple binding sites for the GABA receptor complex have also been mentioned in insects (Robinson et al. 1986 ). Otherwise, the K i value of PF1022A for [2,3-3 H(N)]-GABA binding obtained in this preparation seems higher than that required to inhibit the mobility of Angiostrongylus cantonensis (Terada 1992 ). This observation is consistent with our previous finding (Terada et al. 1982 ) that the effective concentration was variable for one anthelmintic compound required to inhibit different parasites. A further experiment using the membrane preparation of A. cantonensis for radioligand binding shall be performed.
Binding of [butyl-4-3 H]-baclofen in the present study cannot represent GABA B receptors because the agents (5-aminovaleric acid) selective for GABA B receptors failed to compete with it (Table 2 ). PF1022A displaced [butyl-4-3 H]-baclofen binding only at high concentrations and was without unity as reflected in the displaced slope. Also, piperazine did not modify the binding of [butyl-4-3 H]-baclofen. The binding of [butyl-3-3 H]-baclofen seem accidental since it was affected only by compounds possessing a similar chemical structure. Indeed, Ascaris muscle lacks an electrophysiological response to baclofen (Holden-Dye et al. 1988 ). The inhibition produced by PF1022A can thus be attributed as nonspecific.
In conclusion, the results obtained in the present study suggest that PF1022A has an ability to bind with GABA receptors in A. suum muscle, and this finding is helpful in explaining the gabergic action of PF1022A.
